Sarepta Therapeutic (NASDAQ: SRPT) stock fell sharply on Tuesday after the company said the FDA considers an Eteplirsen NDA "premature ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE